CAR T-Cell Therapy for Multiple Myeloma Market Pipeline Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CAR T-Cell Therapy for Multiple Myeloma – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “CAR T-Cell Therapy for Multiple Myeloma – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs Chapters

This segment of the CAR T-Cell Therapy for Multiple Myeloma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs

• PHE 885: Novartis Pharmaceuticals

Novartis drug candidate, PHE 885, is in its phase I trials. The study is to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR). The drug is in the development for the treatment of multiple myeloma.

• JNJ-68284528: Janssen Biotech

Janssen’s drug JNJ-68284528 is currently being evaluated for the treatment of CAR T-Cell Therapy for Multiple Myeloma. The drug is in pre-registration and from the class CAR-T cell therapies. The drug has been designated with orphan drug status.

CAR T-Cell Therapy for Multiple Myeloma: Therapeutic Assessment

This segment of the report provides insights about the different CAR T-Cell Therapy for Multiple Myeloma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in CAR T-Cell Therapy for Multiple Myeloma

There are approx. 5+ key companies which are developing the therapies for CAR T-Cell Therapy for Multiple Myeloma. The companies which have their CAR T-Cell Therapy for Multiple Myeloma drug candidates in the mid to advanced stage and in early stage, i.e. phase I include, Novartis Pharmaceuticals and others.

The report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CAR T-Cell Therapy for Multiple Myeloma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Multiple Myeloma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Multiple Myeloma drugs.

CAR T-Cell Therapy for Multiple Myeloma Report Insights

• CAR T-Cell Therapy for Multiple Myeloma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

CAR T-Cell Therapy for Multiple Myeloma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing CAR T-Cell Therapy for Multiple Myeloma drugs?
• How many CAR T-Cell Therapy for Multiple Myeloma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-Cell Therapy for Multiple Myeloma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Multiple Myeloma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CAR T-Cell Therapy for Multiple Myeloma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Janssen Biotech
• Yake Biotech
• Celgene Corporation

Key Products

• PHE 885
• JNJ-68284528
• APRIL CAR-T cells
• bb 2121

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3lqgel

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900